Effects of TGFbeta on bone ingrowth in the presence of polyethylene particles.
We implanted bone harvest chambers (BHCs) bilaterally in ten mature male New Zealand white rabbits. Polyethylene particles (0.3+/-0.1 microm in diameter, 6.4 x 10(12) particles/ml) were implanted for two, four or six weeks bilaterally in the BHCs, with subsequent removal of the ingrown tissue after each treatment. In addition to the particles, one side also received 1.5 microg of recombinant transforming growth factor beta1 (TGFbeta1). At two weeks, the bone area as a percentage of total area was less in chambers containing TGFbeta compared with those with particles alone (7.8+/-1.3% v 16.9+/-2.7% respectively; 95% confidence interval (CI) for difference -14.0 to -4.30; p = 0.002). At four weeks, the percentage area of bone was greater in chambers containing TGFbeta compared with those with particles alone (31.2+/-3.4% v 22.5+/-2.0% respectively; 95% CI for difference 1.0 to 16.4; p = 0.03). There were no statistical differences at six weeks, despite a higher mean value with TGFbeta treatment (38.2+/-3.9% v 28.8 +/-3.5%; 95% CI for difference -4.6 to 23.3; p = 0.16). The number of vitronectin-receptor-positive cells (osteoclast-like cells) was greater in the treatment group with TGFbeta compared with that with particles alone; most of these positive cells were located in the interstitium, rather than adjacent to bone. TGFbeta1 is a pleotropic growth factor which can modulate cellular events in the musculoskeletal system in a time- and concentration-dependent manner. Our data suggest that there is an early window at between two and six weeks, in which TGFbeta may favourably affect bone ingrowth in the BHC model. Exogenous growth factors such as TGFbeta may be a useful adjunct in obtaining osseointegration and bone ingrowth, especially in revisions when there is compromised bone stock and residual particulate debris.
Goodman
S B
SB
Stanford University Medical Centre, California 94305, USA.
Song
Y
Y
Chun
L
L
Regula
D
D
Aspenberg
P
P
D000818:Animals; D001842:Bone and Bones / Q000166:cytology / Q000378:metabolism; D007150:Immunohistochemistry; D020007:Implants, Experimental; D008297:Male; D016348:Osseointegration; D010316:Particle Size; D011095:Polyethylenes; D011817:Rabbits; D019030:Receptors, Vitronectin / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D013977:Tibia / Q000601:surgery; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D011095:Polyethylenes; D019030:Receptors, Vitronectin; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta